Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
The SpaceX mission
A privately owned unmanned rocket blasts off on a mission to be the first commercial flight to the International Space Station. Slideshow
AIDS drug cocktails saving lives: study
NEW YORK |
NEW YORK (Reuters Health) - Taking a cocktail of powerful AIDS drugs appears to have cut the average death rate by half in a group of people infected with HIV, the virus that causes AIDS, who were followed for an average of more than three years.
In absolute terms, the reduction in death rate translated into a 5 percent increase in 5-year survival for those who started combination HIV therapy compared with those who did not.
The introduction of combination therapy for HIV infection in 1996 has greatly improved immune function in patients infected with the virus. The impact of HIV therapy on overall survival, however, remained unclear, Dr. Miguel A. Hernan, of the Harvard School of Public Health, Boston, and colleagues note in the latest issue of the journal AIDS.
To test whether combined HIV therapy was actually saving lives, the team examined data from 12 European and US studies involving 62,760 HIV-infected patients new to HIV therapy who were followed for an average of 3.3 years.
During follow up, a total of 2039 patients died. After the researchers allowed for factors that might influence death rates, they found that the risk of death was 52 percent lower in those who initiated combination HIV therapy relative to those who did not.
Combined HIV therapy, the investigators note, "halved the (death) rate of HIV-infected individuals in developed countries, and...the absolute reduction in (death) was stronger in those with worse prognosis at the start of follow-up."
This finding, the team concludes, "demonstrates the benefits of being treated even at the most advanced stages of (disease)."
The current findings, Hernan added in an email to Reuters Health, "can be used to inform policy models and cost-effectiveness calculations in Western populations."
SOURCE: AIDS, January 2, 2010.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Why would following participants for three+ years and documenting their death rates be in any manner easy, whether they be from USA, EUROPE, or AFRICA?
I think MaggieBlue needs to read the article again. Your comments are unfounded and not related to anything said in this article.
The DR and his team are trying to establish scientifically whether or not HIV drug cocktails are saving lives in developed countries and points out that developing countries may benefit from the results of the study with respect to cost or policy making.




Follow Reuters